The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Nonsteroidal Anti-Androgens
  • Oncogene Proteins, Fusion
  • Prostatic Neoplasms

abstract

  • Our results, combined with those from earlier studies, provide suggestive evidence that men with TMPRSS2:ERG positive tumors may have longer prostate cancer survival after ADT. Larger cohorts are needed for more robust results and to assess whether men with tumors harboring the fusion benefit from treatment with ADT in the (neo) adjuvant or metastatic setting specifically.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4424159

Digital Object Identifier (DOI)

  • 10.1002/pros.22973

PubMed ID

  • 25728532

Additional Document Info

start page

  • 897

end page

  • 906

volume

  • 75

number

  • 9